EyePoint, Inc. (EYPT) Q1 2026 Earnings Call Transcript

EyePoint, Inc. (EYPT) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 6, 2026

EyePoint Reports First Quarter 2026 Financial Results and Highlights Recent Corporate Developments

WATERTOWN, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced financial results for the first quarter ended March 31, 2026, and highlighted recent corporate developments.

GlobeNewsWire • May 6, 2026

EyePoint (EYPT) Reports Q1 Loss, Tops Revenue Estimates

EyePoint (EYPT) came out with a quarterly loss of $0.99 per share versus the Zacks Consensus Estimate of a loss of $0.79. This compares to a loss of $0.65 per share a year ago.

Zacks Investment Research • May 6, 2026

EyePoint to Report First Quarter 2026 Financial Results on May 6, 2026

WATERTOWN, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, May 6, 2026 to report its first quarter 2026 financial results and highlight recent corporate developments.

GlobeNewsWire • Apr 29, 2026

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

WATERTOWN, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).

GlobeNewsWire • Apr 16, 2026

EyePoint sues rival Ocular Therapeutix, alleging false claims about eye drug

EyePoint filed a lawsuit on Friday accusing rival Ocular Therapeutix of spreading false or misleading information ​about EyePoint and its lead experimental eye ‌drug.

Reuters • Mar 20, 2026

This Biotech Stock Up Nearly 100% in a Year Has Drawn a New $20 Million Share Investment

Parkman bought 1,088,033 shares of EyePoint in the fourth quarter, marking a new stake for the fund. The quarter-end value of the EyePoint position increased by $19.88 million as a result.

The Motley Fool • Mar 15, 2026

EyePoint, Inc. (EYPT) Q4 2025 Earnings Call Transcript

EyePoint, Inc. (EYPT) Q4 2025 Earnings Call Transcript

Seeking Alpha • Mar 4, 2026

EyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate Developments

– Both pivotal Phase 3 trials for DURAVYU in wet AMD on track for data readout beginning in mid-2026 – – Patients dosed in both COMO and CAPRI Phase 3 clinical trials for DURAVYU in DME – – Michael Campbell appointed Chief Commercial Officer to lead launch strategy and readiness for DURAVYU – – Over $300 million of cash and investments on December 31, 2025, providing runway into Q4 2027 – WATERTOWN, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced financial results for the fourth quarter and full-year ended December 31, 2025, and highlighted recent corporate developments.

GlobeNewsWire • Mar 4, 2026

EyePoint (EYPT) Reports Q4 Loss, Tops Revenue Estimates

EyePoint (EYPT) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.78. This compares to a loss of $0.64 per share a year ago.

Zacks Investment Research • Mar 4, 2026